Literature DB >> 33201407

High expression of NEK2 promotes gastric cancer progression via activating AKT signaling.

Hao Wan1, Lin Xu2, Huangbin Zhang1, Feixiang Wu1, Weiqiang Zeng1, Taiyuan Li3.   

Abstract

Never in mitosis gene A-related kinase 2 (NEK2) has been recognized as an oncogene involved in the initiation and progression of various human cancers. However, our knowledge is still lacking in regard to the function of NEK2 in gastric cancer, the most common cancer in Eastern Asia associated with poor prognosis. Therefore, in the present study, we investigated the association of NEK2 with gastric cancer. We found that the development of gastric cancer is associated with NEK2 overexpression, particularly in patients with large tumor size and lymph node metastasis. We also provided evidence that NEK2 overexpression binds to and inhibits protein phosphatase 1 (PP1), which subsequently activates AKT and the downstream oncogenic pathways. As a result, via AKT/HIF1α axis, the glucose metabolism is reprogrammed towards aerobic glycolysis to provide rapid energy for the growth of gastric cancer cells. Moreover, the autophagic activity is suppressed via AKT/mTOR axis, leading to impaired response to cancer treatment and enhanced cell survival. In contrast, inactivating AKT by NEK2 silencing decreases aerobic glycolysis and promotes autophagic cell death, which eventually inhibits the growth of gastric cancer cell. All these results revealed that NEK2 promotes gastric cancer progression via activating AKT-mediated signaling pathways, which expanded our knowledge on gastric cancer pathogenesis and also provided novel target for clinical treatment.

Entities:  

Keywords:  AKT signaling pathway; Aerobic glycolysis; Autophagy; Gastric cancer; NEK2

Year:  2020        PMID: 33201407     DOI: 10.1007/s13105-020-00776-8

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  34 in total

Review 1.  The Nek2 protein kinase: a novel regulator of centrosome structure.

Authors:  Andrew M Fry
Journal:  Oncogene       Date:  2002-09-09       Impact factor: 9.867

2.  The Prognostic Significance of NEK2 in Hepatocellular Carcinoma: Evidence from a Meta-Analysis and Retrospective Cohort Study.

Authors:  YuSheng Cheng; XiaoLong Chen; LinSen Ye; YinCai Zhang; Jing Liang; Wei Liu; BoXuan Zhou; ShiYang Zheng; Yiming Huang; GuiHua Chen; YiNan Deng; Qi Zhang; Yang Yang
Journal:  Cell Physiol Biochem       Date:  2018-12-12

3.  Dishevelled is a NEK2 kinase substrate controlling dynamics of centrosomal linker proteins.

Authors:  Igor Cervenka; Jana Valnohova; Ondrej Bernatik; Jakub Harnos; Matej Radsetoulal; Katerina Sedova; Katerina Hanakova; David Potesil; Miroslava Sedlackova; Alena Salasova; Zachary Steinhart; Stephane Angers; Gunnar Schulte; Ales Hampl; Zbynek Zdrahal; Vitezslav Bryja
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-02       Impact factor: 11.205

Review 4.  Targeting NEK2 as a promising therapeutic approach for cancer treatment.

Authors:  Yanfen Fang; Xiongwen Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

5.  Gene expression profile of serial samples of transformed B-cell lymphomas.

Authors:  Sven de Vos; Wolf-Karsten Hofmann; Thomas M Grogan; Utz Krug; Mathew Schrage; Thomas P Miller; Jonathan G Braun; William Wachsman; H Phillip Koeffler; Jonathan W Said
Journal:  Lab Invest       Date:  2003-02       Impact factor: 5.662

6.  Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells.

Authors:  Ulrika Andréasson; Michael Dictor; Mats Jerkeman; Mattias Berglund; Christer Sundström; Johan Linderoth; Richard Rosenquist; Carl A K Borrebaeck; Sara Ek
Journal:  Am J Hematol       Date:  2009-12       Impact factor: 10.047

7.  Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.

Authors:  Reinaldo Franqui-Machin; Mu Hao; Hua Bai; Zhimin Gu; Xin Zhan; Hasem Habelhah; Yogesh Jethava; Lugui Qiu; Ivana Frech; Guido Tricot; Fenghuang Zhan
Journal:  J Clin Invest       Date:  2018-06-04       Impact factor: 14.808

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  NIMA related kinase 2 promotes gastric cancer cell proliferation via ERK/MAPK signaling.

Authors:  Wei-Dong Fan; Tao Chen; Peng-Jun Liu
Journal:  World J Gastroenterol       Date:  2019-06-21       Impact factor: 5.742

10.  Reconstruction of an integrated genome-scale co-expression network reveals key modules involved in lung adenocarcinoma.

Authors:  Gholamreza Bidkhori; Zahra Narimani; Saman Hosseini Ashtiani; Ali Moeini; Abbas Nowzari-Dalini; Ali Masoudi-Nejad
Journal:  PLoS One       Date:  2013-07-11       Impact factor: 3.240

View more
  3 in total

Review 1.  The Metabolism Reprogramming of microRNA Let-7-Mediated Glycolysis Contributes to Autophagy and Tumor Progression.

Authors:  Chien-Hsiu Li; Chiao-Chun Liao
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

2.  Overexpression of NEK2 is correlated with poor prognosis in human clear cell renal cell carcinoma.

Authors:  Chenfeng Wang; Yan Huang; Xin Ma; Baojun Wang; Xu Zhang
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

3.  NEK2 Serves as a Novel Biomarker and Enhances the Tumorigenicity of Clear-CellRenal-Cell Carcinoma by Activating WNT/β-Catenin Pathway.

Authors:  Jiancheng Zhou; Jiawei Lai; Yongyi Cheng; Weixing Qu
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-29       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.